Reading IOVA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IOVA free→Reading IOVA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IOVA free→QuarterlyIQ Insights · IOVA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 193…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the “ Board ”) of Iovance Biotherapeutics, Inc. (the “ Company ”), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company’s annual meeting of stockholders (the “ Annual Meeting ”) currently anticipated to be held in June…
Results of Operations and Financial Condition. On February 24, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Secu…
Results of Operations and Financial Condition. On November 6, 2025, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of…
Entry Into a Material Definitive Agreement. On August 22, 2025, Iovance Biotherapeutics, Inc. (the “ Company ”) entered into an Amended and Restated Open Market Sale Agreement (the “ Agreement ”) with Jefferies LLC (“ Jefferies ”) with respect to an at the market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through Jefferies, acting as sales agent, up to $350.0 million of shares of the Company's common stock, par value $0.000041666 pe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on August 6, 2025, Corleen Roche was appointed as Chief Financial Officer of the Company. Ms. Roche will replace Matthew W. Rosinack as the Company’s Principal Financial Officer and Principal Accounting Officer, effective the day after the Company files its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
Results of Operations and Financial Condition. On August 7, 2025, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On July 7, 2025, Iovance Biotherapeutics, Inc. (the “Company”) entered into an Executive Employment Agreement with Corleen Roche (the “Agreement”), pursuant to which Ms. Roche shall be appointed as the new Chief Financial Officer of the Company, effective August 6, 2025 (the “Effective Date”). On the Effective…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on June 10, 2025, Jean-Marc Bellemin notified Iovance Biotherapeutics, Inc. (the “Company”) that he would be resigning as Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer of the Company to pursue other opportunities, effective July 10, 2025. On June 30, 2025, the Company and Mr. Belle…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer and principal financial and accounting officer of Iovance Biotherapeutics, Inc. (the “Company”), provided the Company with written notice under his Executive Employment Agreement, dated November 23, 2020, that he would resign from the Company, effective July 10, 2025, to pursue other…
Results of Operations and Financial Condition. On May 8, 2025, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.